Stay updated with breaking news from Jeff Baxter. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Erickson envisions a souped-up version of the S-64 Air Crane helicopter ferrying vehicles and bulk cargo to U.S. military troops in the field.
By Garrett Reim2021-02-24T21:03:00+00:00 Erickson is pitching the US Army on an autonomous variant of its heavy lift Air Crane helicopter, the S-64F+. The company believes the S-64F+ could compliment the service’s fleet of Boeing CH-47 Chinooks, and also Sikorsky CH-53 heavy lift helicopters, which are operated by the US Marine Corps, by supporting training and logistics operations, it said on 23 February. Source: Erickson Erickson S-64 Air Crane in aerial firefighting configuration The S-64 is a commercial variant of the 1960s-era Sikorsky CH-54 Tarhe, a twin-engined heavy lift helicopter ...
/cloudfront-us-east-1.images.arcpublishing.com/tgam/TBKXUS3FUROBVIPLCZJNHOFD7I.JPG)
The Globe and Mail Bookmark Please log in to listen to this story. Also available in French and Mandarin. Log In Create Free Account Getting audio file ... This translation has been automatically generated and has not been verified for accuracy. Full Disclaimer As COVID-19 was beginning its deadly trek around the globe last year, scientists at biopharmaceutical company VBI Vaccines were asking themselves a key question: Can a vaccine be created to deal with more than one kind of coronavirus? The company, which is headquartered in Cambridge, Mass., and has its research operations in Ott...
Work continues to develop Covid-19 vaccines effective against new coronavirus variants. And some researchers are eyeing an even more ambitious goal: to create broad-spectrum vaccines protective against new types of virus - even before they emerge. Researchers have warned, however, that there are significant technical hurdles to overcome before such “pan-virus” or “pan-coronavirus” vaccines could be released. Here's what we know so far: Why do we need a better vaccine? Events in recent decades – and not just the latest pandemic – have highlighted the possible need for such widely a...
VBI Vaccines is due to start a Phase 1/2 study of a coronavirus vaccine candidate in Q1 2021, after a preclinical hamster challenge study demonstrated ‘robust immunogenicity and efficacy’. The Cambridge, Massachusetts headquartered company is working on two candidates. The most advanced, VBI-2902, is a monovalent vaccine candidate expressing the SARS-CoV-2 spike protein. VBI-2901, meanwhile, is a trivalent pan-coronavirus vaccine candidate expressing the SARS-CoV-2 (COVID-19), SARS-CoV (SARS), and MERS-CoV (MERS) spike proteins. Both candidates set for clinical...